Accelerate your precision oncology drug development

Incorporate real-world clinical genomic insights to improve your biomarker-driven clinical trial design, with potential impact on inclusion and exclusion criteria, endpoint selection, and stratification of treatment regimen. With data from over 175,000 patients, our GuardantINFORM™ real-world clinical-genomic platform is one of the largest of its kind. This robust dataset offers insights into anti-cancer therapy use in the clinic, tumor evolution, and treatment resistance throughout each patient’s treatment journey.

Utilize GuardantINFORM at all phases of drug development:

Targeted drug development

Identify, characterize, and prioritize patients with biomarker-defined cancers and in need of treatment options for potential new drug development indications and label expansions.

Clinical trial optimization

Incorporate real-world clinical-genomic data into clinical trial design, control arm simulation, clinical operations activities, and clinical development decision-making.

Post-marketing studies

Conduct health outcomes and safety studies of on- and off-label use of marketed therapies using real-world market insights and estimates of progression-free and overall survival in biomarker-defined cancers.

Guardant Inform

Our database by the numbers

+

Cancer types

+

Distinct cancer treatments

+

Distinct cancer-related procedures

+

Patients with >1 Guardant360 test

~ K

Patients with integrated clinical and molecular information

GuardantINFORM™ enables research on topics such as acquired resistance, the presence of specific alterations impacting the efficacy of a drug, and the impact of co-occurring biomarkers on clinical outcomes, across over 60+ cancer types.
Mapping the longitudinal patient journey with real-world evidence
The GuardantINFORM™ database reconstructs an mNSCLC patient journey and assesses real-world duration of first line aNSCLC targeted therapy following ctDNA biomarker identification. Source: Yu J, Marino E, Hanna D, et al. Real-world first line targeted therapy duration following ctDNA testing in advanced non small cell lung cancer. Journal of Thoracic Oncology. S689, MARCH 1, 2021
Calculating real-world outcomes
These GuardantINFORM™ data demonstrate outcomes for first line targeted aNSCLC treatment base using the Guardant360® test. These results show similar outcomes to tissue guided first line targeted therapy. Source: Yu J, Marino E, Hanna D, et al. Real-world first line targeted therapy duration following ctDNA testing in advanced non small cell lung cancer. Journal of Thoracic Oncology. S689, MARCH 1, 2021

Contact Us

If you are interested in partnering with Guardant Health to accelerate your precision oncology drug development, contact us or email: biopharmabd@guardanthealth.com.